Financial results for the quarter and year ended March 31, 2026.
RPGLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 13.5 pts more than Nifty Microcap 250 and 13.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
RPG Life Sciences reported audited Q4 FY26 and full-year results with an unmodified auditor opinion. Revenue from operations for the full year grew about 8.3% YoY to Rs. 70,752 lakhs, while Q4 revenue jumped roughly 24% YoY to Rs. 17,689 lakhs. However, profit after tax for FY26 fell about 37% to Rs. 11,517 lakhs (vs Rs. 18,324 lakhs in FY25), and Q4 PAT dropped sharply to Rs. 2,990 lakhs from Rs. 11,735 lakhs a year ago, mainly because FY25 had a one-time Rs. 10,018 lakh gain from surplus land assignment. Exceptional items in FY26 were a net gain of Rs. 390 lakhs, comprising a Rs. 2,475 lakh insurance claim settlement on the API plant fire, offset by a Rs. 1,169 lakh impact from new labour codes and a Rs. 916 lakh intangible asset write-off. The Board recommended a Rs. 24 per share dividend (300% on face value) and appointed Dr. Pratit Samdani as an additional independent director. Cash and equivalents strengthened to Rs. 11,568 lakhs from Rs. 2,870 lakhs, while operating cash flow remained positive at Rs. 5,650 lakhs.
Mixed picture for shareholders: solid topline growth, especially in Q4, and a generous 300% dividend signal strong cash generation, but sharply lower PAT and EBITDA margin compression (from ~26% to ~24%) reflect the absence of last year's one-time land gain and ongoing cost pressures. Watch profitability trends excluding exceptional items for a cleaner read on core business momentum.